PepGen reports positive Phase 2 FREEDOM2 data for PGN-EDODM1 in DM1; splicing correction 22.9% ex-outlier

PepGen Inc.

5 mg/kg cohort (n=8): mean splicing correction 7.3% overall, 22.9% excluding outlier; placebo 6.8%.
No serious adverse events; all TEAEs mild/moderate; nausea most common; no renal toxicity.
Middle finger vHOT showed improvement trend vs placebo worsening; returned to baseline at Week 16.
10 mg/kg cohort >50% enrolled; data expected 2H 2026; cash sufficient into 2H 2027.
Mean muscle PGN-EDODM1 concentration 158 ng/g in 5 of 6 treated patients (one pending).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.